News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|July 10, 2024

Factors Influencing Treatment Choice in Spasticity

Author(s)Khashayar Dashtipour, MD, PhD, Francois Bethoux, MD, Jennifer Smith, PA

A panel of experts discuss variation in spasticity between patients and the role disease severity can play.

Episodes in this series

Video 1 - 4 KOLs are feature in, "Definition and Pathophysiology of Spasticity"

EP. 1 Definition and Pathophysiology of Spasticity

Video 2 - 4 KOLs are feature in, "Changes in Presentation of Spasticity Over Time"

EP. 2 Changes in Presentation of Spasticity Over Time

4 KOLs are featured in this series.

EP. 3 Impact of Spasticity of Patient and Caregiver’s Quality of Life

4 KOLs are featured in this series.

EP. 4 Factors Influencing Treatment Choice in Spasticity

4 KOLs are featured in this series.

EP. 5 Treatment Options for Spasticity

4 KOLs are featured in this series.

EP. 6 Planning Spasticity Treatment Based on Patient Goals

4 KOLs are featured in this series.

EP. 7 Defining Severe Spasticity

4 KOLs are featured in this series.

EP. 8 Intrathecal Baclofen for Management of Severe Spasticity

4 KOLs are featured in this series.

EP. 9 Baclofen Pump for Treatment of Severe Spasticity

4 KOLs are featured in this series.

EP. 10 Managing Safety Concerns with ITB Pump

4 KOLs are featured in this series.

EP. 11 Ideal Candidates for ITB Pump

4 KOLs are featured in this series.

EP. 12 Long-term Data with ITB Pumps for Spasticity

A panel of 4 experts on spasticity

EP. 13 ITB Pump for Spasticity: Surveillance Registry Findings

A panel of 4 experts on spasticity

EP. 14 Practical Considerations when Using ITB Pump for Spasticity

A panel of 4 experts on spasticity

EP. 15 Potential for Use of ITB Pump Earlier in Spasticity

A panel of 4 experts on spasticity

EP. 16 Trends in Treatment of Spasticity

A panel of 4 experts on spasticity

EP. 17 Advice for Clinicians Treating Spasticity

Discuss the variation in spasticity presentation among patients and within the same patient.
1. How do you factor in this variability when recommending treatments?
What roles do disease severity, anatomical distribution, and comorbidities play in choosing among different options?
How important is it to understand triggers of spasticity or underlying disability causes when managing moderate/severe spasticity?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Fradique Moreira, MD

Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease

ByLouie Pasculli

October 28th 2025

Overviewing Long-Term Efficacy of Zorevunersen From IEC 2025

ByJoseph Sullivan, MD

October 28th 2025

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

October 28th 2025

Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited

October 28th 2025

Camille Carroll, MD

Rethinking Inclusion Criteria to Increase Generalizability, Patient Participation in Parkinson Disease Trials: Camille Carroll, MD

ByCamille Carroll, MD,Isabella Ciccone, MPH

October 28th 2025

Latest CME

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Carrie M. Hersh, DO, MSc, FAAN; Anna Shah, MD

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

James F. Howard Jr, MD; Nicholas J. Silvestri, MD, FAAN; Neelam Goyal, MD

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

Alireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

October 31, 2025

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited

Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding

Key Diagnostic Pearls for NMOSD Recognition and Testing: Elena Grebenciucova, MD

Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease

© 2025 MJH Life Sciences^®

All rights reserved.